He, X, Huang, Q., Ma, C., Yu, S., McKernan, R. and Cook, J.M. (2000) Pharmacophore/receptor models for GABAA/BzR ?2?3?2, ?3?3?2 and ?4?3?2 recombinant subtypes. Including volume analysis and comparison to ?1?3?2, ?5?3?2 and ?6?3?2 subtypes. Drug Design and Discovery, 17, 131-171.

has been cited by the following article:

• TITLE: 3-Arylisothiazoloquinols As Potent Ligands for the Benzodiazepine Site of GABAA Receptors

  AUTHORS: Jakob Nilsson, Elsebet Østergaard Nielsen, Tommy Liljefors, Mogens Nielsen, Olov Sterner

  KEYWORDS: Isothiazolo[5, 4-b]quinolin-4(9H)-ones; Isoxazolo[5, 4-b]quinolin-4(9H)-ones; Benzodiazepine binding site; GABAA Receptors; GABAA Receptor Subtypes; Pharmacophore Model

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.5 No.1, January 12, 2012

  ABSTRACT: 3-Arylisothiazolo[5,4-b]quinolin-4(9H)-ones and 3-arylisoxazolo[5,4-b]quinolin-4(9H)-ones were synthesized and assayed for affinity for the benzodiazepine binding site of the GABAA receptors. While the 3-arylisothiazoloquinolin-4-ones were found to be potent ligands, with affinities (expressed as the affinity Ki value) down to 1 nM, the 3-arylisoxazoloquinolin-4-ones are less potent. This is suggested to depend on sterical repulsive interaction of the 3-arylisoxazoloquinolin-4-ones with the receptor essential volume of the binding site, and a higher electron density at the nitrogen in the azole ring (N-2) as well as the carbonyl oxygen in the isothiazoloquinolin-4-ones enabling them to interact stronger with hydrogen bond donor sites at the binding site.